UniQure outlines urgent FDA engagement for AMT-130 as BLA timing turns uncertain
Source: SeekingAlpha
2025-11-10 11:12:25 ET
More on uniQure
- uniQure N.V. (QURE) Q3 2025 Earnings Call Transcript
- UniQure: Controversy Abounds As Stock Price Halves On FDA News
- uniQure: 3-Year Huntington's Data Move AMT-130 From 'Promising' To 'Probable' (Rating Upgrade)
- uniQure Q3 2025 Earnings Preview
- uniQure stock falls after FDA feedback on gene therapy application
Read the full article on Seeking Alpha
For further details see:
UniQure outlines urgent FDA engagement for AMT-130 as BLA timing turns uncertain
uniQure N.V.
NASDAQ: QURE
QURE Trading
18.55% G/L:
$20.035 Last:
2,309,692 Volume:
$17.97 Open:
QURE Latest News
April 30, 2026 07:05:00 am
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease
QURE Stock Data
$1,555,111,367
59,307,892
N/A
61
N/A
Biotechnology & Life Sciences
Healthcare
NL
Amsterdam
